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Abstract
Accurate and efficient genome-wide detection of copy number variants (CNVs) is essential for understanding human
genomic variation, genome-wide CNV association type studies, cytogenetics research and diagnostics, and independent
validation of CNVs identified from sequencing based technologies. Numerous, array-based platforms for CNV detection exist
utilizing array Comparative Genome Hybridization (aCGH), Single Nucleotide Polymorphism (SNP) genotyping or both. We
have quantitatively assessed the abilities of twelve leading genome-wide CNV detection platforms to accurately detect Gold
Standard sets of CNVs in the genome of HapMap CEU sample NA12878, and found significant differences in performance.
The technologies analyzed were the NimbleGen 4.2 M, 2.1 M and 36720 K Whole Genome and CNV focused arrays, the
Agilent 161 M CGH and High Resolution and 26400 K CNV and SNP+CGH arrays, the Illumina Human Omni1Quad array and
the Affymetrix SNP 6.0 array. The Gold Standards used were a 1000 Genomes Project sequencing-based set of 3997
validated CNVs and an ultra high-resolution aCGH-based set of 756 validated CNVs. We found that sensitivity, total number,
size range and breakpoint resolution of CNV calls were highest for CNV focused arrays. Our results are important for cost
effective CNV detection and validation for both basic and clinical applications.
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Introduction
Copy Number Variations (CNVs) are a major component of
human genomic variation and are thought to be important
contributors to phenotypic diversity and human disease [1]. These
unbalanced chromosomal rearrangements include duplications,
deletions and insertions with respect to a reference genome and lie
in the size continuum of genomic variation between small
insertions/deletions (indels; 1–1000 bp) and whole chromosomal
aneuploidies (multiples of 10 Mbps). Individual CNV events may
be benign or pathogenic and can manifest different phenotypes
depending on the genomic context of the variant [1,2]. Multiple
studies have mapped CNVs genome-wide in individual genomes
using several different technologies e.g. [3–11]. Such studies aim to
catalog the complement of CNVs within a single genome and to
understand their relationships to functional elements, including
their implications for normal and disease associated phenotypes.
These efforts are curated in databases such as the Database of
Genomic Variants (DGV) (http://projects.tcag.ca/variation/).
The extent to which CNVs exist in the human genome has not
been exhaustively assessed. However, numerous efforts including
the recent release of data from the 1000 Genomes Project [12]
suggest that the distribution of CNVs in the genome is biased
towards multiple hotspots including segmental duplications and
away from genes encoding protein complexes and other dosage
sensitive genes [3,8,13,14]. CNVs affect a significantly larger
fraction of the genome than Single Nucleotide Polymorphims
(SNPs) and may encompass several percent of the genome [3,8].
To date, three main technologies are used for accurate and
high-resolution genome-wide CNV mapping [15]; 1) array
Comparative Genome Hybridization (aCGH), 2) SNP and SNP
plus CGH combination array platforms and 3) 2
nd generation
sequencing technologies [14,16–18]. Sequencing based technolo-
gies are theoretically able to provide base pair resolution of CNV
events. However, there remain several obstacles to using only
sequencing based methods for CNV mapping. At present, it is still
relatively expensive to sequence a genome to the required depth of
coverage (currently at least ,206) for reliable detection of CNVs
greater than 1 kb [3,12]. Moreover, it is still difficult to execute
large-scale genome-wide association type studies due to the limited
sample throughput of current 2
nd generation DNA sequencing
formats. Furthermore, the requisite computational analysis
pipelines for identifying CNVs from whole genome sequence data
have immense hardware and software requirements. A combina-
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CNVs in a sequenced genome [3], and these algorithms are not
yet mature enough to be used routinely on the many terabytes of
sequencing data generated per genome. In addition, mapping
short sequencing reads to non-unique regions of the genome is
ambiguous. Over the last 5 years however, increasingly dense and
sometimes targeted oligonucleotide arrays for CNV detection have
been developed. These have co-evolved with robust and
straightforward experimental procedures and with platform
specific CNV mining software that can be employed in a
reasonably powerful desktop computing workstation. Genome-
wide mapping of CNVs by array-based platforms has become a
standard approach in phenotype association studies, e.g. [19,20]
clinical cytogenetics e.g. [21] as well as a standard validation tool
for CNVs called from whole genome sequence data [3,8]. As such,
array based technologies are likely to be used for CNV mapping
for some time.
Currently there are multiple, widely used array platforms that
vary in methodology, coverage of the genome, resolution of CNV
calls, workflow, and subsequently in ability to accurately and
comprehensively detect CNVs. Here we assess the performances of
the leading array based platforms for genome-wide CNV detection
in the HapMap [22] CEU sample NA12878 against two Gold
Standard datasets (GSs). This study differs from previous platform
comparisons [23–26] in that we have compared the abilities of
these platforms to detect known, experimentally validated CNV
events genome-wide by taking advantage of the recently released,
independent lists of CNVs from the 1000 Genomes Consortium
[3,12] and ultra high-resolution aCGH [8]. These CNV sets are
considered the most accurate and complete sets of CNV calls for
any genome currently available. The platforms that were
compared were the Roche NimbleGen 4.2 M, 2.1 M and
36720 K whole genome (WG) and CNV focused designs, the
Agilent 161 M CGH and High Resolution and 26400 K CNV
focused and CGH+SNP designs, the Illumina Omni1Quad and
the Affymetrix SNP 6.0 arrays.
We attempted to carry out an unbiased comparative analysis of
the practical utilities of these platforms to detect known CNVs in
this sample by using data from experiments carried out by the
platform manufacturers and the recommended software. We
compared the size range, total number, and resolution of the CNV
calls from each platform to those of the Gold Standard sets. In
addition, we calculated the sensitivity of each platform and found
enormous differences. We also showed that each platform detects
additional CNVs that are not included in the stringent Gold
Standard sets. Finally, for the platforms that require control
samples, we investigated the value of using control DNA from a
single sequenced individual compared with that from a pool of
individuals. We found that the use of a single genome control led
to higher performance. These studies are important for maximiz-
ing value from the many thousands of CNV probing experiments
performed each year.
Results
Genome-wide CNV detection by twelve platforms
We compared the genome-wide CNV detection abilities of
twelve different array-based platforms from four different
manufacturers (summarized in Table 1): Roche NimbleGen
(hereafter referred to as NimbleGen) 4.2 M, 2.1 M and
36720 K whole genome (WG) and CNV focused designs, Agilent
161 M CGH and High Resolution designs and 26400 K CNV
focused and CGH+SNP designs, Illumina Human Omni1Quad
and Affymetrix SNP 6.0 arrays. These platforms differ in a
number of features including total number of probes and their
spacing; these and other experimental details are also included in
Table 1. Additionally, we compared two different conditions
(single genome control versus pool of genomes) for the two
NimbleGen 2.1 M designs. Thus a total of 14 different platform
CNV sets are compared in this paper.
DNA from the same sample, HapMap [22] CEU sample
NA12878, which has been extensively characterized by the 1000
Genomes Project [12], was hybridized to each platform. In most
cases, hybridizations were performed either by the company that
manufactures the arrays or by a service provider; however, one set
of NimbleGen experiments was performed by us, and the
Affymetrix SNP 6.0 array data was already published. Two
technical replicates were performed for all experiments. For most
cases the control DNA was comprised of the individual HapMap
CEU sample NA10851, which matched published results used in
our Gold Standard set (see below). However, for one Agilent
platform the well-characterized HapMap CEU NA12891 DNA
was used. Analyses of the raw data for generating the CNV lists
were carried out using the manufacturers’ software and recom-
mended parameter settings as described in the methods.
The different platforms called from 103 (NimbleGen 2.1 M
Whole Genome against pool) to 1981 (NimbleGen 2.1 M CNV)
total CNVs (Table S1) in the genome of NA12878. Only one
independently validated CNV (57 kb) was detected by all
platforms (Figure 1) and many other CNVs were unique to
individual or distinct sets of platforms. The CNV that was detected
by all platforms falls within an Olfactory Receptor gene cluster, a
known CNV hotspot [27]. This common CNV has been reported
by several studies using diverse methods e.g. [6,8,28,29]. The 1000
Genomes Project reports this CNV as two distinct events, a 57 kb
deletion on one allele and a 53 kb deletion on the other allele
entirely contained within the bounds of the 57 kb deletion.
However, aCGH cannot differentiate these two alleles and calls
the CNV as a single event. Interestingly the breakpoints lie in
consecutive segmental duplications indicating that this event is
likely to be mediated by non-allelic homologous recombination of
these segmental duplications [30]. In addition, the probe tracks
show that the probe densities for the twelve arrays are highly
variable. The size distributions of the CNVs called by each
platform are shown in Fig. 2. More than 50% of events called by
the NimbleGen CNV focused arrays are less than 2 kb in size,
with up to 36%,500 bp; this result is expected since these arrays
have high tiling density in known CNV regions and the largest
number of probes. More than 50% of the Illumina Omni1Quad
calls are ,3 kb whereas ,50% of the Agilent 26400 K CNV calls
are ,6 kb. More than 80% of CNVs called by the NimbleGen
4.2 M and 36720 K WG designs and Agilent 161 M CGH and
26400 K CGH+SNP arrays are 1–500 Kb in size. More than
90% of CNVs called by the NimbleGen 2.1 M WG, Agilent
161 M High Resolution and the Affymetrix SNP 6.0 arrays are in
the 1–500 kb size range. All the arrays have a similar frequency
distribution of CNV calls in the larger size ranges. The size
distributions of the Gold Standard CNV sets (described below) are
shown for reference. More than 50% of the 1000GP Gold
Standard CNVs are less than 500 bp (75%,1 kb) while more
than 50% of the 42 M Gold Standard CNVs are 500 bp-3 kb in
size.
The Different Platforms Can Detect Many Known CNVs
To determine the relative performances of the different
platforms we compared the CNV sets obtained from each array
to Gold Standard datasets. Two independent sets of Gold
Standard CNVs (GS CNVs) were assembled: one set was from
Comparative Analysis of CNV Detection Arrays
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other from a study that used ultra-high resolution aCGH [8]. The
1000 Genomes Project Gold Standard (1000GP GS) is the set of
experimentally validated sequence-based CNV calls found in
NA12878 by the 1000 Genomes Project July 2010 data release.
The final set of 3997 unique CNVs in the genome of NA12878
was determined at base pair resolution using Read Depth, Split
Read and Paired-end analysis of 2nd generation sequencing data.
Each CNV in the final set was validated by aCGH (NimbleGen or
Agilent custom arrays) or by PCR. The validated CNV calls from
this sequence data are thought to be the most accurate set of calls
for this sample to date [3]. We also used a second gold standard,
the Roche NimbleGen 42 million aCGH Gold Standard (42 M
GS). This is the list of CNVs found in the genome of NA12878 by
aCGH using a set of 20 NimbleGen arrays containing ,42 million
long oligo probes (50–75 bp) in total tiling the non-repetitive
portion of the genome (median spacing ,56 bp) and by using
NA10851 as a control (the same control that we used). This set
consists of 756 unique CNVs .450 bp in size and containing a
minimum of 10 consecutive probes per CNV. Validation of a
Table 1. Summary of CNV detection platforms and experiments.
Platform
Total
Features
Median
Probe
Spacing
Data
Source
Technical
Replicates
Control
Sample Analysis
Total CNVs
Replicate 1,
Replicate 2
Total CNV
Overlap with
1000G GS
Total CNV
Overlap with
42 M GS
aCGH Platforms
Roche NimbleGen
Human CGH 4.2 M
WG Tiling Array
4,200,000
(50–75mers)
284 bp NimbleGen 2 NA10851 NimbleScan 2.6
(converted to
HG18 using
LiftOver from UCSC)
425,465 83, 87 115, 112
Roche NimbleGen
Human CNV 4.2 M
Array
4,200,000
(50–75mers)
284 bp Service
Provider
2 NA10851 NimbleScan 2.6
(converted to
HG18 using
LiftOver from UCSC)
1926, 1883 408, 386 310, 275
Roche NimbleGen
Human CGH 2.1 M
WG Tiling Array
2,100,000
(60mers)
1.1 kb NimbleGen 2 NA10851 NimbleScan 2.6 498, 482 73, 78 98, 95
Snyder 2 Pool of 7
females
(Promega)
229, 103 47, 18 64, 22
Roche NimbleGen
Human CNV 2.1 M
Array
2,100,000
(50–75mers)
1.2 kb
(backbone)
NimbleGen 2 NA10851 NimbleScan 2.6 1939, 1981 286, 299 251, 253
Snyder 2 Pool of 7
females
(Promega)
481, 605 66, 63 21, 24
Roche NimbleGen
Human CGH 36720 K
WG Tiling Array
720,000
(60mers)
2.5 kb NimbleGen 2 NA10851 NimbleScan 2.6 206, 187 24, 26 29, 29
Roche NimbleGen
Human CNV 36720 K
Array
720,000
(50–75mers)
4.8 kb
(backbone)
NimbleGen 2 NA10851 NimbleScan 2.6 819, 897 160, 179 166, 178
Agilent SurePrint G3
Human CGH
Microarray, 161M
963,029
(60mers)
2.1 kb overall
(1.8 kb in
RefSeq Genes)
Service
Provider
2 NA10851 AGW6.5 825, 879 57, 59 94, 76
Agilent SurePrint G3
Human High
Resolution
Microarray, 161M
963,331
(60mers)
2.6 kb Service
Provider
2 NA10851 AGW6.5 (converted
to HG18 using
LiftOver from UCSC)
1566, 1604 91, 90 114, 107
Agilent SurePrint G3
Human CNV
Microarray, 26400 K
442,892
(60mers)
1 kb in CNVs Service
Provider
2 NA10851 AGW6.5 (converted
to HG18 using
LiftOver from UCSC)
1055, 1002 49, 128 158, 184
aCGH+SNP Platforms
Agilent SurePrint G3
Human CGH+SNP
Microarray, 26400 K
292,097 (CGH)
(60mers)
119,091 (SNP)
7.2 kb overall
(4.5 kb in
Refseq genes)
Agilent 2 NA12891 AGW6.5 (converted
to HG18 using
LiftOver from UCSC)
120, 126 4, 5 15, 16
Illumina Human
Omni1-Quad
BeadChip
1,140,419
(SNP)
1.2 kb Service
Provider
2 N/A GenomeStudio
2010.2 (converted
to HG18 using
LiftOver from UCSC)
251, 267 62, 68 122, 122
Affymetrix SNP 6.0 946,000 (CGH)
(25mers)
906,000 (SNP)
CN 2.2 kb
SNP 1.3 kb
Overall 0.7 kb
Mc. Carroll
et al.
1 N/A Birdseed 162 49 67
doi:10.1371/journal.pone.0027859.t001
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designed Agilent CNV genotyping array [8]. Because the resolution
of this aCGH experiment far exceeds that of the platforms that were
analyzed in this paper, this validated set could be used as a gold
standard. We realize that the use of a NimbleGen specific gold
standard for comparing NimbleGen platforms to those of other
manufacturers may be of concern. However, the trends observed in
our comparison generally agree regardless of the gold standard
used, so we believe any such potential bias is negligible. These two
different gold standard sets are complementary since they were
derived from differing technologies that have different abilities to
detect CNVs (summarized in Table 2). In total, only 255 (6%)
1000GP GS CNVs (corresponding to 205 (27%) 42 M GS CNVs)
occur in both sets using the 50% reciprocal overlapping criterion
described below.
We assessed the performance of each array by several metrics
including the number of GS CNVs detected, their size, their
breakpoint resolution (i.e. the platform CNV size relative to defined
GS breakpoints), the sensitivity of each platform and the number of
non-GSCNVs calledby each platform. To determine thevalidity of
a platform CNV call we used an extension of the criterion
established by the 1000 Genomes Project for counting two different
CNV calls as the same event [3]: a platform CNV is considered
Figure 1. Detection of a known 57 kb CNV on chromosome 1q44 by twelve different array platforms. Depicted are the log2 ratios of
NA12878 to the control genome and locations along the chromosome for each probe (blue dot) in this region. Gene, 1000 Genomes Project Gold
Standard CNVs (1000GP CNVs) and Segmental Duplication (SD) tracks are shown. The CNV highlighted in the red box was called by both replicates for
all twelve platforms using the manufacturer-recommended software and parameters. Red arrows indicate examples of additional array-specific CNV
calls. A. NimbleGen 4.2 M Whole Genome, B. NimbleGen 4.2 M CNV, C. NimbleGen 2.1 M Whole Genome, D. NimbleGen 2.1 M CNV, E. NimbleGen
36720 K Whole Genome, F. NimbleGen 36720 K CNV, G. Agilent 161 M CGH, H. Agilent 161 M High Resolution, I. Agilent 26400 K CNV, J. Agilent
26400 K CGH+SNP, K. Illumina Human Omni1Quad, L. Affymetrix SNP 6.0.
doi:10.1371/journal.pone.0027859.g001
Figure 2. Size distributions of CNV call sets. Data include CNVs
from all replicates of the fourteen different experiments listed in table 1
(twelve different platforms and two different conditions for NimbleGen
2.1 M arrays). The size distributions of the two Gold Standards are
overlaid for reference. The apparent frequency spikes are results of the
changing bin size.
doi:10.1371/journal.pone.0027859.g002
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reciprocally, or there exists a set of GS CNVs such that each
member of the set overlaps the platform call by at least 50% of the
GS CNV size and the total number of base pairs of the platform call
that overlap some member of this set of GS CNVs is at least 50% of
the size of the platform call. Henceforth, any further mention of
overlap will imply these criteria unless otherwise stated.
Each platform identified many GS CNVs. A summary of the
sizes of the GS CNVs detected by each platform is shown in
Figure 3. Overall, the greatest absolute number of GS CNVs
Table 2. Summary of possible relationships between reference, experimental control and test genomes and the resulting abilities
of different methods to detect CNVs in the test genome (with respect to the reference genome).
Genome relationships
at a given locus
Test CNV detection by
aCGH against Control
Test CNV in 1000GP Gold Standard
(against Reference Genome)
Test CNV in 42 M aCGH Gold
Standard (against Control)
Test?Control=Reference yes yes yes
Test?Control?Reference yes yes yes
Test=Control?Reference no yes (but those .500 bp were removed
from our GS for fairer comparison)
no
Test=Control=Reference no no no
Test=Reference?Control yes no yes
Copy Number Variants in one genome can only be defined with respect to a reference genome. Comparisons to different reference genomes will produce different sets
of CNVs for the same test genome. Sequencing based methods directly compare the test genome to the reference genome. For array-based methods however, this
comparison is indirect as an experimental control genome is also required. The relationship between the reference genome and this control genome determines which
CNVs in the test sample (with respect to the reference genome) are detected.
doi:10.1371/journal.pone.0027859.t002
Figure 3. Resolution of array platform CNV calls for known Gold Standard CNVs. Each data point plots the size of a platform CNV versus
the size of the corresponding Gold Standard CNV that individually overlaps the platform call by 50% reciprocally. Events overlapping the 1000GP GS
CNVs are shown in blue. Events overlapping the 42 M GS CNVs are shown in pink. Total numbers of data points and R
2 values are indicated in the
table below. Data is an aggregate of all events from two technical replicates for each platform except the Affymetrix SNP 6.0. The size distribution and
total number of platform CNVs that overlap Gold Standard CNVs in this way are also clearly visible.
doi:10.1371/journal.pone.0027859.g003
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CNV (619 1000GP GS CNVs, 385 42 M GS CNVs) followed in
order from most GS CNVs detected to least by the NimbleGen
2.1 M CNV, 36720 K CNV, Agilent 26400 K CNV, Agilent
161 M High Resolution, NimbleGen 4.2 M WG, Illumina
Omni1Quad, NimbleGen 2.1 M WG, Agilent 161 M CGH,
Affymetrix SNP 6.0, NimbleGen 36720 K WG and Agilent
26400 K CGH+SNP (10 1000GP GS CNVs, 16 42 M GS
CNVs) platforms. This order is largely preserved regardless of the
gold standard used.
For CNVs greater than 10 kb, 10–71 1000GP GS CNVs and
11–88 42 M GS CNVs were detected. The largest numbers of
1000GP GS and 42 M GS CNVs .10 kb in size were detected by
the NimbleGen 4.2 M CNV and the Agilent 26400 K CNV
arrays respectively while the smallest numbers were detected by
the Agilent 26400 K CGH+SNP array. In addition to the larger
CNVs, most of the platforms detected much smaller CNVs albeit
with reduced sensitivity. The NimbleGen 4.2 M CNV array
detected the largest numbers of GS CNVs ,10 kb in size (548
1000GP GS CNVs and 322 42 M GS CNVs). The smallest GS
CNVs are detected by the NimbleGen CNV focused designs
followed by the Agilent 26400 K CNV and the NimbleGen
4.2 M WG designs, the Illumina OmniQuad, the Agilent 161M
designs and the Affymetrix SNP 6.0, the NimbleGen 2.1 M WG
array, the NimbelGen 36730 K WG array and finally the Agilent
26400 K CGH+SNP array. The platforms with the highest probe
densities in known CNV regions are the ones that detect the
largest numbers of GS CNVs and also the smallest GS CNVs. At
the extremes, the NimbleGen CNV focused arrays can detect GS
CNVs ,100 bp, whereas the smallest GS CNV detected by the
Agilent CGH+SNP array is on the order of 10 kb.
For each platform, the sizes of the platform calls were generally
similar to those of the overlapping GS CNVs. These results
indicate that when a CNV is detected, its breakpoints are
reasonably accurate.
Sensitivities of the Different Platforms
The average sensitivity to each gold standard was calculated
for each platform (Figure 4). Sensitivities ranged from 0.01
(Agilent 26400 K CGH+SNP) to 0.64 (NimbleGen 4.2 M
CNV). The platform CNVs that overlapped detectable GS
CNVs by 50% reciprocally were counted as true positives
(Figure 5a). Since the overlap criteria do not necessarily imply a
one-to-one overlap between a platform CNV and a GS CNV,
the overlapping CNVs were counted with respect to the GS
CNVs. The NimbleGen 4.2 M CNV array clearly stands out
with the highest sensitivity followed by the NimbleGen 2.1 M
CNV and 36720 K CNV arrays while the Affymetrix SNP 6.0,
NimbleGen 36720 K WG and the Agilent SNP+CGH arrays
have the lowest sensitivities regardless of the GS used. The
NimbleGen 4.2 M and 2.1 M WG designs, the Agilent 161M
and 26400 K CNV designs, and the Illumina Omni1Quad all
have comparable sensitivities with some platforms performing
slightly better than others depending on the GS used. Raw
sensitivities for all the platforms were very low (Figure S1). In the
process of generating a maximally unbiased report of sensitivity,
we noted that a large subset of GS CNVs (.80% of 1000GP GS
and ,40% of 42MGS) were not detectable by any platform
(Figure 5b). We therefore defined detectable sets of GS CNVs to
be the subsets of GS CNVs detected by at least one platform. We
used these detectable GS CNV sets to report corrected
sensitivities here. Most GS CNVs are detected by relatively few
platforms and only two CNVs from each gold standard are found
in all 14 platform CNV lists (the two GS CNVs are detected as
one single platform CNV). We further assessed the platform
distribution of the GS CNVs detected only by one platform
(Figure 5c). The CNV focused platforms detect .80% of these
platform-specific 1000GP GS CNVs. The NimbleGen 4.2 M
CNV, Agilent 26400 K CNV and Illumina Omni1Quad arrays
detect the majority of the platform-specific 42 M GS CNVs
(.20% each).
Figure 4. Array sensitivities to detecting Gold Standard CNVs. Depicted are the average corrected platform sensitivities based on two
technical replicates for each platform, except the Affymetrix SNP 6.0. Corrected sensitivities were calculated using only those Gold Standard CNVs
that were detectable by at least one platform. Blue bars show sensitivity to the detectable 1000GP GS and pink bars show sensitivity to the detectable
42 M GS.
doi:10.1371/journal.pone.0027859.g004
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We analyzed in detail the number of platforms that can identify
each detectable GS CNV as a function of size using our overlap
criteria (Figure 6). In general, as shown in the figure the larger
events are detected by more platforms. Events detected by 8 or
more platforms are often .2.5 kb in size. However, there are still
many large GS CNVs that are missed by most platforms; 50% of
detectable 1000GP GS CNVs and 44% of detectable 42 M GS
CNVs greater than 50 kb are found by only 4 or fewer platforms
(for the 1000GP GS the majority of these were found by they
NimbleGen 2.1 designs and the 36720 K WG array; for the 42 M
GS the majority of these were found by Agilent CNV array). The
smaller CNVs are detected by only a few platforms. 98% of
detectable 1000GP GS CNVs and 89% of detectable 42 M GS
CNVs less than 2 kb are found by four or fewer platforms.
Interestingly, several (275 1000GP GS and 12 42 M GS) GS
CNVs less than 500 bp are detectable by commercial arrays. In
summary, there are many CNVs both large and small that are
detected by only a limited number of platforms.
All Platforms Detect Many Non-Gold Standard CNVs
Across all platforms, large percentages (70–96% for 1000GP GS
and 52–93% for 42 M GS) of platform calls are not in the gold
standards sets (Figure S2). At the extremes, 52% of the Illumina
Omni1Quad CNVs did not overlap with the 42 M GS whereas
96% of the Agilent 26400 K CGH+SNP CNVs did not overlap
with the 1000GP GS by our criteria. These platform calls may fall
into several categories; some may be false positives, some may be
undetectable by sequencing based CNV methods, some may be
true but not included in the gold standards for various reasons
including inability to validate using PCR or custom aCGH or due
to the very strict requirements for inclusion into the 42 M GS.
More CNVs are Detected Using a Single Genome Control
versus a Pooled Control
We expect to call at least twice as many CNVs from an aCGH
experiment using a single individual genome as a control versus a
pool of genomes. This is because the call set from the aCGH
experiment against a single control comprises both test (NA12878)
and control (NA10851) CNVs without any way of differentiating
from which genome an individual CNV signal originated.
However, in an aCGH experiment using a pool of genomes as a
control, the signals of many rare CNVs that are present in
individual genomes of the control pool are expected to be too weak
to be detected. Thus, the call set from such an experiment is likely
only to contain CNVs from the test genome (NA12878). This
trend was observed for the NimbleGen 2.1 M whole genome and
CNV focused arrays. For the NimbleGen 2.1 M whole genome
array, approximately three times as many calls were made when
the NA 10851 DNA was used as a control (490 average CNVs)
relative to the pooled reference (166 average CNVs). For the
NimbleGen 2.1 M CNV focused array ,3.6 times as many CNVs
were called using the single control (1960 average CNVs) relative
to the pool (543 average CNVs) (Table 1). Thus, more CNVs can
Figure 5. Array detectable Gold Standard CNVs. (a) Venn diagram showing overlap of CNV calls from a single platform (NimbleGen 2.1 M CNV)
with the detectable 1000 Genomes Gold Standard. (b) The percentage of Gold Standard CNVs that were detected by at least one technical replicate
of each platform is shown for all platforms (including twelve different platforms and two conditions for the NimbleGen 2.1 M arrays). Blue bars
indicated percentage of 1000GP GS CNVs and pink bars indicate percentage of 42 M GS CNVs. (c) Platform distribution of all Gold Standard CNVs that
are detected by only one platform.
doi:10.1371/journal.pone.0027859.g005
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aCGH experiment as opposed to using a pool of genomes as the
control.
As expected, more CNVs from experiments using a single
control overlapped with both GS CNV sets than those from
experiments using a pooled control. For a given platform, the size
distributions and resolutions of the validated calls are comparable
regardless of the control used (Figure 3c–e). In addition, we
calculated higher sensitivities to both gold standards for experi-
ments using a single individual as a control than for those using a
pooled control (bars 3–6 of Figure 4 and Figure S1). The sensitivity
of the NimbleGen 2.1 M whole genome array was twice as high
when a single genome was used as a control compared to when a
pool of genomes was used. The sensitivity of the NimbleGen
2.1 M CNV focused array was 5–7 times higher when a single
genome was used as a control than when a pool of genomes was
used. These results indicate that aCGH experiments using an
individual sequenced control sample may provide a valuable
means for maximal CNV detection.
Discussion
CNVs form an important class of human genetic variants.
Understanding their functional impacts requires accurate, com-
prehensive and efficient genome-wide mapping [1]. This study
evaluated the abilities of the current generation of array-based
CNV detection platforms to detect known CNVs genome-wide.
There are fundamental differences between CGH, CGH+SNP
and SNP only platforms. These include differences in methodol-
ogies (single versus dual channel experiments and scanning signal
acquisition) and in physical attributes of the arrays (probe type and
oligomer length) [15]. For example, SNP and combination array
CNV calls are based on single channel experiments where the
control and test DNA samples are hybridized to different arrays
leading to less reliable log2 ratios of the signal intensity of test DNA
to control DNA than for aCGH. However, SNP arrays also
combine SNP genotype data (the proportion of minor alleles to
total alleles at a locus) to complement log2 ratio data for CNV
calling. aCGH platforms rely exclusively on log2 ratios for CNV
calling. Because of such differences we have tried to assess only the
practical utilities of the various platforms for CNV calling.
Consequently, we have compared only the final lists of CNV calls
from each platform for a particular genome (NA12878) based on
the experimental and data analysis protocols recommended by
each array manufacturer. In our comparison we assume that all
platforms contain probes that are optimized to be maximally
informative at their specific loci. This assumption allows
interpretation of our results based on probe distributions and
probe numbers regardless of probe type (CGH or SNP). We note
that many different algorithms are available for extracting CNV
data from all of the platforms reviewed here. Algorithm and
parameter effects can result in highly variable CNV call sets from
the same raw array data. Such algorithm effects are reviewed
elsewhere [26] and are beyond the scope of this manuscript.
Therefore we have chosen to assess only the practical utilities of
these platforms which we believe include the use of the best
manufacturer recommended algorithms and parameters, as these
are the most likely analyses that will be carried out by users.
Most array platforms attempt to balance unbiased whole
genome novel CNV discovery and focused genotyping in known
CNV regions under the restraint of fixed probe numbers by
employing intelligent probe distributions. For SNP arrays
(Affymetrix and Illumina), probe distributions are restricted by
the non-uniform availability of informative SNPs throughout the
genome [9]. It is especially difficult to find informative SNPs to
sample repetitive regions, where many CNVs occur [14,15]. In
contrast, for CGH arrays, probes can be selected with a more even
genome-wide distribution in general, and with higher density in
certain regions as desired. Sometimes, aCGH probes can be
designed to unique stretches of sequence in repetitive regions even
in the absence of SNPs. Consequently most SNP arrays are now
complemented by additional CGH probes [9]. We found that
probe distribution greatly affects the performance of a platform.
By all metrics including total number of platform calls, size
range of calls, resolution of calls and platform sensitivity, the
NimbleGen and Agilent CNV focused arrays were the top
Figure 6. Number of array platforms detecting each Gold Standard CNV by size. Each data point represents the number of platforms that
detect a certain Gold Standard CNV by at least one technical replicate using our overlap criteria versus the size of the Gold Standard CNV. Only
detectable Gold Standard CNVs are shown. Blue points correspond to 1000GP GS CNVs and pink points correspond to 42 M GS CNVs.
doi:10.1371/journal.pone.0027859.g006
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CNV focused designs had more than four times as many total calls
and sensitivities that were at least two times higher compared to
the corresponding unbiased designs with the same numbers of
probes. Additionally, these arrays (along with the Illumina
Omni1Quad array) detected the largest size range of CNV events
from ,500 bp-1 Mbp. Furthermore, the NimbleGen 36720 K
CNV and Agilent 26400 K CNV designs consistently performed
better than arrays with even more probes such as the NimbleGen
4.2 M WG, 2.1 M WG, Agilent 161 M designs, Illumina
Omni1Quad and the Affymetrix SNP 6.0. Additionally when
comparing the Agilent 161 M gene focused CGH array against
the evenly tiled High Resolution array we see that probe
distribution affects the performance of the arrays whereby the
evenly tiled array outperforms the gene-centric design albeit by
only small margin. We conclude that probe distribution appears to
be the dominant factor affecting array performance in this study.
CNV focused designs outperform more evenly tiled designs that in
turn outperform gene-focused designs in detecting CNVs genome-
wide.
It is expected that arrays containing more probes will detect
larger numbers of CNVs genome-wide and call breakpoints that
are generally closer to the true endpoints CNVs than arrays with
fewer probes. This is because CNVs can only be detected in
genomic regions for which probes exist. When comparing arrays
with similar probe distributions (whole genome or CNV focused),
we do find the expected trend of arrays with more probes
performing better than those with fewer; the NimbleGen 4.2 M
whole genome and CNV designs perform better than the
corresponding 2.1 M designs which perform better than the
36720 K designs which perform better than the corresponding
Agilent 26400 K designs. However, the total number of probes
does not appear to be a sufficient predictor of CNV detection
ability. Rather, for the current generation of arrays, probe
selection seems to be the most important factor in optimizing
CNV detection.
It is expected that a paucity of probes in certain regions will lead
to the inability of an array to make robust CNV calls in those
regions. We suspect that this is the primary reason why such large
fractions of the GS CNV sets are not detected by any of the
platforms (,80% of the 1000GP GS CNVs and ,40% of the
42 M GS CNVs are not detected). There is a large percentage of
CNVs in the 1000GP GS (22% Alus, 1% LINEs) that are too
repetitive to be tiled by aCGH probes or to contain informative
SNPs, and will consequently not be detected by any of the tested
platforms. No Alu in the 1000GP GS was detectable by any array
platform. The 42 M GS does not contain any SINE or LINE
repeats. Furthermore, 75% of CNVs in the 1000GP GS and 18%
CNVs in the 42 M GS are less than one 1 kb in size. We do not
expect most platforms to detect CNVs ,1 kb in size even in
unique sequence. This is because most of the array platforms do
not contain enough probes to provide the required probe density
to detect such small events genome-wide. The CNV focused arrays
sometimes contain the required probe density for detecting certain
small CNVs without compromising backbone probe density.
These platforms also detect the largest subsets of the GS CNVs
that are detected by a single platform only, for the same reason.
Thus, while the numerical values are specific to this study the
trends of array performance reported here are as expected.
Our performance metrics do not take into account the
additional genome-wide SNP data provided by several of these
platforms (Agilent GCH+SNP, Illumina, Affymetrix). It will
depend on a given study design to determine whether additional
SNP information is worth the seemingly reduced sensitivity of
CNV detection by these platforms. The recent availability of
platforms such as the Illumina Omni2.5 M array with 2.5 million
SNP and CGH probes may increase the ability of these platforms
to detect both CNVs and SNPs. However, optimized analyses for
detecting CNVs from these arrays are not yet available, and thus
they were excluded from this study. Ultimately, as whole genome
sequencing costs continue to drop and analysis methods for
extracting CNV (and Structural Variation in general), SNP and
mobile element insertion data become more developed, the utility
of arrays will be replaced by the availability of the entire spectrum
of genomic variation at base pair resolution [12]. In the near
future however, because of both cost considerations and the
orthogonal information provided relative to sequencing, array
methods are likely to continue to be used for large-scale CNV
studies in biological and medical research, validation of sequenc-
ing-based CNV data [3] and for routine clinical diagnostics [21].
In this study we specifically analyzed known CNVs in a
European sample relative to European controls. This undoubtedly
led to biases in CNV detection especially since some of the arrays
(NimbleGen and Agilent CNV focused arrays, Illumina Omni1-
Quad and Affymetrix SNP 6.0 arrays) were designed to detect
CNVs found in the 1000 Genomes Project pilot trios. These trios
include the Caucasian trio of which NA12878 is the daughter and
a Yoruban trio [3,12]. Thus, the results obtained may differ when
analyzing different combinations of ethnicities.
All the platforms called large numbers of non-GS CNVs. While
some of these observations are certainly false positives, it is unlikely
that ,80% of all calls on any single array are false. More
plausibly, many of these array-detected non-GS CNVs may be
true CNVs that do not occur in the gold standards for several
reasons. Both gold standards were assembled using extremely strict
requirements. The 1000GP GS comprised only experimentally
validated calls. However, validation by PCR and aCGH was
attempted only on a subset of the total calls [3]. Additionally, the
1000GP calls were made using three different analyses; Read
Depth, Paired-end and Split Read analysis. Each of these methods
has specific limitations. Read depth will not call CNVs that occur
in highly repetitive elements (SINEs and LINEs). Split read and
Paired-end analyses produce less confident calls using the short
reads (36 bp) of the 1000 Genomes pilot data as these are less
likely to map uniquely to the reference genome. Therefore we
expect and observe little overlap of the calls from these three
methods as noted by the 1000 Genome Project [3]. However, the
CNVs used in our Gold Standard are only those that were found
by at least two out of three computational methods and
experimentally validated; it is likely that many real CNVs exist
but were detected by one method only, not validated or entirely
missed. For inclusion into the 42 M GS, CNVs were required to
contain at least 10 probes in sequence [8]. However, there may be
many CNVs containing less than 10 probes. We conclude that
there may be many true platform calls that do not occur in the
gold standards due to the stringent inclusion criteria. Another
reason why such large numbers of platform calls did not overlap
with GS CNVs could be due to the overlap criterion that was used.
We required 50% reciprocal overlap to count two CNV calls as
the same. However, the breakpoints of CNVs obtained from
array-based methods can be up to several kb from the true
breakpoints. Hence there may be true events called by the
platforms that are not counted as valid in our analyses because the
overlap may be less than 50%.
Lastly, we addressed the important issue as to whether a single
genome is a more informative control than a pool of genomes for
aCGH. An aCGH experiment using a single genome control will
miss all the CNVs with respect to the reference that are exactly the
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using a single control that is well characterized for CNVs by some
orthogonal method. The rationale for using a pool of individual
genomes as the control is to eliminate this loss due to the
expectation that at most loci, the copy number of most of genomes
of the pool will be the same as that of the reference. Thus, the
effects of rare CNVs in individual genomes of the pool are diluted.
However, for polymorphic loci in which a significant subset of the
genomes of the pool contain the same CNV as the test sample, that
CNV may not be called in the test sample as the signal would be
dampened. For cancer samples or other heterogeneous tissue, this
problem can be exacerbated against a normal control as the
heterogeneity of the tissue leads to an even more dampened signal.
We found that using a single individual genome as a control
provided more CNV calls and higher sensitivities than using a pool
of genomes as a control.
In conclusion we have shown that under the recommended
manufacturers’ experimental and analytical conditions, there is
enormous variability in performance of the current generation of
widely used commercial CNV detection arrays. The arrays best
able to detect known CNVs in a well characterized European
sample are those that contain dense probe tiling in known CNV
regions while not compromising the backbone tiling density of the
rest of the genome.
Methods
Sample Selection
All individual samples analyzed in this study were chosen from
the 1000 Genomes Project [12] and previously from the
International HapMap Project [22]. The test sample, NA12878,
was chosen because of extensive prior genomic characterization
including ,426sequence coverage in the 1000 Genomes Project
and ultra-high resolution array Comparative Genome Hybridiza-
tion [8]. NA12878 is a Utah resident of European Ancestry (CEU)
and is the daughter in one of the two trios sequenced at high
coverage in the 1000 Genomes Pilot Project. The control sample
NA10851 was also chosen from extensive genomic characteriza-
tion including its use as the control in ultra-high resolution aCGH
and as a 1000 Genomes Project low coverage sample [8,12].
NA10851 is a male of European Ancestry from Utah (CEU).
NA12891, the father of NA12878, was used as the control for the
Agilent CGH+SNP 26400 K array. Genomic DNA for these
samples was obtained from the Coriell Institute for Medical
Research. An additional control, a pool of 7 females (Promega,
Cat # G1521) was chosen because it is a commercially available,
reproducible pool of individual genomes.
Gold Standard CNV sets for NA12878
Two complementary Gold Standard sets of CNVs found in the
genome of NA12878 were used in this study. These are the 1000
Genomes Project Gold Standard and the Roche NimbleGen 42
million aCGH Gold Standard described below.
1000 Genomes Project Gold Standard (1000GP GS). The
1000 Genomes Project Gold Standard is the set of validated CNVs
found in the genome of NA12878 by the 1000 Genomes Project
[3,12] during the recently completed pilot phase of the effort. The
set consists of sequence-based NA12878 CNV calls (using the
inner confidence interval coordinates) from the July 2010 data
release that were validated by aCGH (NimbleGen or Agilent
custom arrays) or PCR. Deletion data and duplication data were
obtained from:
ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/pilot_data/release/
2010_07/trio/sv/
ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/pilot_data/release/
2010_07/low_coverage/sv/
ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/pilot_data/paper_
data_sets/companion_papers/mapping_structural_variation/.
Only those calls that were made in the genome of NA12878 and
contained the word ‘validated’ at least once in the validation
column were included. The set was further pruned by removing all
calls where the start coordinate was larger than the end
coordinate. In addition, NA10851 CNVs occurring in this set
were removed so as not to confound the findings. NA10851 CNVs
were called using CNVnator [17] from the low coverage 1000
Genomes sequence data. The final set consists of 3997 unique
CNVs. The 1000 Genomes Project utilized a variety of methods
including Read Depth, Split Read and Paired-end mapping to call
high quality, base pair resolution CNVs from next generation
sequencing data on NA12878. The CNV calls from this sequence
data are thought to be the most accurate set of calls for this sample
to date [3].
Roche NimbleGen 42 million aCGH Gold Standard (42 M
GS). The Roche NimbleGen 42 million aCGH Gold Standard
is the set of published CNVs found in NA12878 using NA10851 as
a control on a set of 20 Roche NimbleGen arrays each containing
,2.1 million long-oligo probes (50–75 bp) tiling the non-repetitive
portion of the genome (median spacing ,56 bp). The parameters
were set to detect CNVs greater than 500 bp [8]. The total set
consists of 756 unique CNVs. The resolution of this aCGH
experiment exceeds that of the platforms being compared in this
paper, and hence the calls from this data are likely to be more
accurate in size and breakpoint resolution than those from the
platforms being compared here. Thus, this set was used as a Gold
Standard. In order to call CNVs from this data, strict criteria were
used including a minimum of 10 consecutive probes to call an
event. A subset of calls was validated by qPCR and by aCGH on a
custom designed Agilent CNV genotyping array based on the
initial CNV call set [8].
Generation of Platform CNV sets for NA12878
NA12878 CNV call sets from twelve different array-based
platforms from four different manufacturers were compiled using
raw data obtained from either the manufacturer or a service
provider followed by data processing using the manufacturers’
recommended software and parameters. The platforms used were
the NimbleGen 4.2 M, 2.1 M and 36720 K whole genome and
CNV focused designs, Agilent 161 M CGH and High Resolution
designs and 26400 K CNV focused and CGH+SNP designs,
Illumina Human Omni1Quad and Affymetrix SNP 6.0 arrays
(summarized in Table 1). Details of how the individual call sets
were compiled are described below.
Roche NimbleGen NA12878 CNV call sets. Raw data from
aCGH experiments performed on six different platforms were
obtained from Roche NimbleGen, Inc. (Madison, WI 53719,
USA). The platforms used were the NimbleGen 4.2 M, 2.1 M and
the 36720 K whole genome and CNV focused arrays. All
experiments used NA12878 DNA as the test sample and
NA10851 DNA as the control sample. In addition, aCGH
experiments were performed by us using the manufacturer’s
protocol with NA12878 DNA as the test sample and a pool of
female genomic DNA as the control on the 2.1 M whole genome
and CNV focused designs. In brief, NA12878 DNA was labeled
with cy3 and the control pool DNA was labeled with cy5. Equal
amounts of the test and control DNA were hybridized to the arrays
for 72 hours. The arrays were washed and scanned in an ozone
free environment using a Roche MS200 scanner. Images were
analyzed using NimbleScan 2.6 software (Roche NimbleGen, Inc.,
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experiments were performed. In order to obtain final CNV call
sets from raw data for each experiment, segtable files were
generated using NimbleScan 2.6 with default settings (min
segment difference=0.2, min number of probes per
segment=2). Segments with 20.25,Log R,0.25 were
removed. For the 4.2 M and 2.1 M designs, segments with ,5
probes per segment were also removed. The 4.2 M designs are
based on HG19 coordinates. These CNV coordinates were
converted to HG18 using the UCSC LiftOver tool [31]. The
coordinates of 425/435 and 465/474 CNV calls from two
technical replicates of the WG array and 1926/1956 and 1883/
1912 CNV calls from two technical replicates of the CNV array
were successfully converted. The remaining CNV coordinates
comprised the final call sets for these arrays.
Agilent NA12878 CNV call sets. Raw data from aCGH
experiments carried out on the Agilent 161 M CGH and High
Resolution designs and 26400 K CNV focused design using
NA12878 DNA as the test and NA10851 DNA as the control were
obtained from service providers. Raw data from hybridizations
and scannings of the Agilent 26400 K CGH+SNP array using
NA12878 DNA as the test and NA12891 DNA as the control were
obtained from Agilent Technologies (Santa Clara CA 95051,
United States). Final CNV call sets were obtained by generating
Interval Based Reports in the Agilent Genomic Workbench 6.5
software package (Agilent Technologies, Santa Clara CA 95051,
United States) using default settings. Chromosomal coordinates for
the resulting CNV calls are based on HG19 (except for the 161M
CGH design). The CNV coordinates were converted to HG18
using the UCSC LiftOver tool [31]. The coordinates of 1566/
1615 and 1604/1651 CNV calls from two technical replicates of
the 161 M High Resolution array were successfully converted.
The coordinates of 1055/1094 and 1002/1045 CNV calls from
two technical replicates of the CNV focused 26400 K array were
successfully converted. The coordinates of 120/124 and 126/129
CNV calls from two technical replicates of the CGH+SNP
26400 K array were successfully converted. The remaining CNVs
comprised the final call sets for these platforms. Technical
replicates for all 26400 K designs are from the same field of
separate arrays.
Illumina NA12878 CNV call sets. Raw data for two
technical replicates of NA12878 DNA hybridized to the Illumina
Human Omni1Quad as per the manufacturer’s protocol were
obtained from a service provider. The data were analyzed using
Genome Studio 2010.2 software (Illumina, Inc., San Diego, CA
92121 USA) in which SNP clustering and genotyping were
performed, B allele frequencies (the proportion of minor (‘B’)
alleles to total (‘A’ and ‘B’) alleles at a locus) were calculated and
log2 ratios were extracted. CNV analysis was carried out using the
CNVpartition 2.4.4 algorithm within Genome Studio using
default parameters (Confidence Threshold=35). The obtained
CNV lists comprised coordinates based on HG19. These
coordinates were converted to HG18 using the UCSC LiftOver
tool [31]. The coordinates of 251/259 and 267/277 calls from the
two technical replicates were successfully converted and comprised
the final lists of NA12878 CNVs from this platform.
Affymetrix NA12878 CNV call set. The set of CNVs found
in the genome of NA12878 by the Affymetrix SNP 6.0 array was
obtained from the supplement of published data [9]. No further
processing was done on this set before including it in the
comparative analyses.
Supporting Information
Figure S1 Array sensitivities to detecting Gold Standard
CNVs. Depicted are the average raw platform sensitivities based
on two technical replicates for each platform, except the
Affymetrix SNP 6.0. Blue bars show sensitivity to the 1000GP
GS and pink bars show sensitivity to the 42 M GS.
(TIF)
Figure S2 Non-Gold Standard Platform CNV discovery
rate. Depicted are the proportions of individual Platform CNV
call sets that do not meet the 50% reciprocal overlapping criteria
with Gold Standard CNVs. Calculations are based on two
technical replicates for each platform except the Affymetrix SNP
6.0. Blue bars show values with respect to the 1000GP GS and
pink bars show values with respect to the 42 M GS.
(TIF)
Table S1 Platform Specific Raw Data. This table contains
the following information for each replicate of all microarray
platforms; total number of CNV calls, total GS overlapping
CNVs, sensitivity calculations (raw and corrected) and false
discovery rate calculations.
(XLS)
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